A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer



Status:Recruiting
Conditions:Breast Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:2/24/2019
Start Date:July 22, 2014
End Date:March 31, 2021
Contact:There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Phone:1-317-615-4559

Use our guide to learn which trials are right for you!

MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer

The main purpose of this study is to compare progression-free survival for women with hormone
receptor positive (HR+), human epidermal growth factor receptor (HER2) negative advanced
breast cancer receiving either abemaciclib + fulvestrant or fulvestrant alone. Participants
will be randomized to abemaciclib or placebo in a 2:1 ratio. The study will last about 9
months for each participant.

For the endocrine naïve cohort, all participants will received abemaciclib + fulvestrant.


Inclusion Criteria

- Have a diagnosis of HR+, HER2- breast cancer

- Have locally advanced disease not amenable to curative treatment by surgery or
metastatic disease. In addition, participants must fulfill 1 of the following
criteria:

- relapsed with radiologic evidence of progression while receiving neoadjuvant or
adjuvant endocrine therapy, with no subsequent endocrine therapy received
following progression

- relapsed with radiologic evidence of progression within 1 year from completion of
adjuvant endocrine therapy, with no subsequent endocrine therapy received
following progression

- relapsed with radiologic evidence of progression more than 1 year from completion
of adjuvant endocrine therapy and then subsequently relapsed with radiologic
evidence of progression after receiving treatment with either an antiestrogen or
an aromatase inhibitor as first-line endocrine therapy for metastatic disease.
Participants may not have received more than 1 line of endocrine therapy or any
prior chemotherapy for metastatic disease

- presented de novo with metastatic disease and then relapsed with radiologic
evidence of progression after receiving treatment with either an antiestrogen or
an aromatase inhibitor as first line endocrine therapy for metastatic disease.
Participants may not have received more than 1 line of endocrine therapy or any
prior chemotherapy for metastatic disease

- for the endocrine naïve cohort: Must not have received prior endocrine therapy in
current or prior disease setting

- Have postmenopausal status due to either surgical/natural menopause or ovarian
suppression (initiated at least 28 days prior to Day 1 of Cycle 1) with a
gonadotropin-releasing hormone (GnRH) agonist such as goserelin

- Have a negative serum pregnancy test at baseline (within 14 days prior to
randomization) and agree to use medically approved precautions to prevent pregnancy
during the study and for 12 weeks following the last dose of abemaciclib if
postmenopausal status is due to ovarian suppression with a GnRH agonist

- Have either measurable disease or nonmeasurable bone only disease

- Have a performance status ≤1 on the ECOG scale

- Have discontinued previous therapies for cancer (including specifically, aromatase
inhibitors, anti-estrogens, chemotherapy, radiotherapy, and immunotherapy) for at
least 21 days for myelosuppressive agents or 14 days for nonmyelosuppressive agents
prior to receiving study drug, and recovered from the acute effects of therapy (until
the toxicity resolves to either baseline or at least Grade 1) except for residual
alopecia or peripheral neuropathy

Exclusion Criteria

- Are currently receiving an investigational drug in a clinical trial or participating
in any other type of medical research judged not to be scientifically or medically
compatible with this study

- Have visceral crisis, lymphangitic spread, or leptomeningeal carcinomatosis visceral
crisis is not the mere presence of visceral metastases but implies severe organ
dysfunction as assessed by symptoms and signs, laboratory studies, and rapid
progression of the disease

- Have clinical evidence or history of central nervous system metastasis

- Have received prior treatment with chemotherapy (except for neoadjuvant/ adjuvant
chemotherapy), fulvestrant, everolimus, or any CDK4/6 inhibitor. For the endocrine
naïve cohort: In addition, have received treatment with any prior endocrine therapy

- Have received treatment with a drug that has not received regulatory approval for any
indication within 14 or 21 days prior to randomization of study drug for a
nonmyelosuppressive or myelosuppressive agent, respectively

- Have received recent (within 28 days prior to randomization) yellow fever vaccination

- Have had major surgery within 14 days prior to randomization of study drug to allow
for post-operative healing of the surgical wound and site(s)

- Have a personal history within the last 12 months of any of the following conditions:
syncope of cardiovascular etiology, ventricular tachycardia, ventricular fibrillation,
or sudden cardiac arrest

- Have inflammatory breast cancer or a history of any other cancer (except nonmelanoma
skin cancer or carcinoma in-situ of the cervix), unless in complete remission with no
therapy for a minimum of 3 years

- Have received an autologous or allogeneic stem-cell transplant

- Have active bacterial or fungal infection, or detectable viral infection

- Have initiated bisphosphonates or approved Receptor activator of nuclear factor
kappa-B (RANK) ligand targeted agents <7 days prior to randomization
We found this trial at
53
sites
?
mi
from
San Marcos, CA
Click here to add this to my saved trials
1045 North 30th Street
Billings, Montana 59101
406-255-8470
Principal Investigator: BROCK WHITTENBERGER
Phone: 406-238-2500
?
mi
from
Billings, MT
Click here to add this to my saved trials
4725 North Federal Highway
Fort Lauderdale, Florida 33308
(954) 771-8000
Principal Investigator: Zdenka Segota
Phone: 954-771-8000
Holy Cross Hospital While spirituality plays an essential role in the way that we minister...
?
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
3840 Broadway
Fort Myers, Florida 33901
(239) 275-6400
Principal Investigator: Lowell Hart
Phone: 239-275-6400
?
mi
from
Fort Myers, FL
Click here to add this to my saved trials
1200 Moursund Street
Houston, Texas 77030
(713) 798-4951
Principal Investigator: Polly Niravath
Phone: 713-798-2400
Baylor College of Medicine Baylor College of Medicine in Houston, the only private medical school...
?
mi
from
Houston, TX
Click here to add this to my saved trials
8940 N Kendall Dr # 300E
Miami, Florida 33176
Principal Investigator: Grace Wang
Phone: 305-595-2141
?
mi
from
Miami, FL
Click here to add this to my saved trials
Anderson, Indiana 46011
Principal Investigator: Shiroo Parshad
Phone: 765-298-2040
?
mi
from
Anderson, IN
Click here to add this to my saved trials
Athens, Georgia 30607
Principal Investigator: Petros Nikolinakos
Phone: 706-353-2990
?
mi
from
Athens, GA
Click here to add this to my saved trials
Aurora, Colorado 80012
Principal Investigator: Sami Diab
Phone: 303-418-7639
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Austin, Texas 78731
Principal Investigator: Debra Patt
Phone: 512-427-9400
?
mi
from
Austin, TX
Click here to add this to my saved trials
Bedford, Texas 76022
Principal Investigator: Thomas Anderson
Phone: 817-359-9089
?
mi
from
Bedford, TX
Click here to add this to my saved trials
BellFlower, California 90706
Principal Investigator: Han Koh
Phone: 619-641-2675
?
mi
from
BellFlower, CA
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Sara Tolaney
Phone: 617-632-5869
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
111 Colchester Ave
Burlington, Vermont 05401
(802) 847-0000
Principal Investigator: Farrah Khan
Phone: 802-847-2610
Fletcher Allen Health Care As Vermont’s University Medical Center, we at Fletcher Allen are committed...
?
mi
from
Burlington, VT
Click here to add this to my saved trials
?
mi
from
East Bentleigh,
Click here to add this to my saved trials
Fayetteville, Arkansas 72703
Principal Investigator: Joseph Beck
Phone: 479-587-1700
?
mi
from
Fayetteville, AR
Click here to add this to my saved trials
Fort Worth, Texas 76104
Principal Investigator: Sanjay Oommen
Phone: 817-850-2011
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Germantown, Tennessee 38138
Principal Investigator: Clyde Jones
Phone: 901-685-5969
?
mi
from
Germantown, TN
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Julio Peguero
Phone: 713-275-3208
?
mi
from
Houston, TX
Click here to add this to my saved trials
Houston, Texas 77024
Principal Investigator: Frankie Holmes
Phone: 713-467-1722
?
mi
from
Houston, TX
Click here to add this to my saved trials
Jonesboro, Arkansas 72401
Principal Investigator: Mazen Khalil
Phone: 870-932-5296
?
mi
from
Jonesboro, AR
Click here to add this to my saved trials
Joplin, Missouri 64804
Principal Investigator: Govinda Brahmanday
Phone: 417-347-4000
?
mi
from
Joplin, MO
Click here to add this to my saved trials
Kansas City, Missouri 64111
Principal Investigator: Timothy Pluard
Phone: 816-932-3300
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
7360 W. Deschutes
Kennewick, Washington 99336
509-783-0144
Principal Investigator: Thomas Rado
Phone: 509-783-4637
Columbia Basin Hematology and Oncology Our collaboration with Seattle Cancer Care Alliance gives you convenient...
?
mi
from
Kennewick, WA
Click here to add this to my saved trials
Lansing, Michigan 48910
Principal Investigator: Deimante Tamkus
Phone: 517-975-9547
?
mi
from
Lansing, MI
Click here to add this to my saved trials
1 Medical Center Dr
Lebanon, New Hampshire 03756
 (603) 650-5000
Principal Investigator: Peter Kaufman
Phone: 603-653-6181
Dartmouth Hitchcock Medical Center Dartmouth-Hitchcock is a national leader in patient-centered health care and building...
?
mi
from
Lebanon, NH
Click here to add this to my saved trials
Memphis, Tennessee 38120
Principal Investigator: Michael Magee
Phone: 901-226-1493
?
mi
from
Memphis, TN
Click here to add this to my saved trials
Minneapolis, Minnesota 55405
Principal Investigator: Michaela Tsai
Phone: 612-884-6300
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Nashville, Tennessee 37203
Principal Investigator: Sarah Cannon Research Inst.
Phone: 615-239-7615
?
mi
from
Nashville, TN
Click here to add this to my saved trials
New York, New York 10032
Principal Investigator: Kevin Kalinsky
Phone: 212-305-1945
?
mi
from
New York, NY
Click here to add this to my saved trials
New York, New York 10029
Principal Investigator: Amy Tiersten
Phone: 212-241-3300
?
mi
from
New York, NY
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Principal Investigator: Maura Dickler
Phone: 646-888-4545
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
Omaha, Nebraska 68124
Principal Investigator: Margaret Block
Phone: 402-691-6971
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Plano, Texas 75075
Principal Investigator: Christopher Stokoe
Phone: 972-867-3577
?
mi
from
Plano, TX
Click here to add this to my saved trials
Quincy, Illinois 62301
Principal Investigator: Karthik Koduru
Phone: 217-277-3500
?
mi
from
Quincy, IL
Click here to add this to my saved trials
Rochester, New York 14621
?
mi
from
Rochester, NY
Click here to add this to my saved trials
Rome, Georgia 30165
Principal Investigator: Dilawar Khan
Phone: 706-528-9110
?
mi
from
Rome, GA
Click here to add this to my saved trials
Saint Louis, Missouri 63110
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Saint Petersburg, Florida 33705
Principal Investigator: Gail Wright
Phone: 727-216-1143
?
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Salem, Virginia 24153
Principal Investigator: Paul Richards
Phone: 540-774-8660
?
mi
from
Salem, VA
Click here to add this to my saved trials
Salt Lake City, Utah 84106
Principal Investigator: Stephan Kendall
Phone: 801-270-2238
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
San Francisco, California 94143
Principal Investigator: Hope Rugo
Phone: 415-353-7288
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
Sioux Falls, North Dakota 57104
Principal Investigator: Sanford Research
?
mi
from
Sioux Falls, ND
Click here to add this to my saved trials
Sioux Falls, North Dakota 57104
Principal Investigator: Miroslaw Mazurczak
Phone: 6053281379
?
mi
from
Sioux Falls, ND
Click here to add this to my saved trials
Sioux Falls, South Dakota 57104
Principal Investigator: Sanford Research
?
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Stanford, California 94305
Principal Investigator: George Sledge
Phone: 650-725-5295
?
mi
from
Stanford, CA
Click here to add this to my saved trials
Tampa, Florida 33612
Principal Investigator: Hatem Soliman
Phone: 813-745-3522
?
mi
from
Tampa, FL
Click here to add this to my saved trials
The Woodlands, Texas 77380
Principal Investigator: US Oncology
Phone: 281-863-1000
?
mi
from
The Woodlands, TX
Click here to add this to my saved trials
12697 E 51st Street South
Tulsa, Oklahoma 74146
918-505-3200
Principal Investigator: Kevin Weibel
Phone: 918-505-3201
Tulsa Cancer Institute, Pllc Now under the new name of Tulsa Cancer Institute, our specialists...
?
mi
from
Tulsa, OK
Click here to add this to my saved trials
Tyler, Texas 75702
Principal Investigator: Svetislava Vukelja
Phone: 903-592-6114
?
mi
from
Tyler, TX
Click here to add this to my saved trials
Walla Walla, Washington 99362
Principal Investigator: James Cunningham
Phone: 509-522-5993
?
mi
from
Walla Walla, WA
Click here to add this to my saved trials
West Palm Beach, Florida 33401
Principal Investigator: Marilyn Raymond
Phone: 561-366-4149
?
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Winston-Salem, North Carolina 27103
Principal Investigator: Judith Hopkins
Phone: 336-277-8800
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials